NCT04847440View on ClinicalTrials.gov

A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions
Hepatitis B, ChronicHepatitis D
Interventions
DRUG

ATI-2173

ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.

DRUG

Viread

Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.

DRUG

AB-729

AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV

Trial Locations (2)

Unknown

"Republican Clinical Hospital Timofei Mosneaga Arensia EM Unit", Chisinau

"Medical Center of Limited Liability Company Harmoniya krasy", Kyiv

Sponsors
All Listed Sponsors
lead

Antios Therapeutics, Inc

INDUSTRY

NCT04847440 - A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection | Biotech Hunter | Biotech Hunter